Nuvectis Pharma, Inc. financial data

Symbol
NVCT on Nasdaq
Location
1 Bridge Plaza, Suite 275, Fort Lee, NJ
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 301 % -27.1%
Debt-to-equity 49.8 % +55.7%
Return On Equity -156 % -10.8%
Return On Assets -104 % +2.41%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 19.3M shares +11.5%
Common Stock, Shares, Outstanding 19M shares +9.68%
Entity Public Float 60M USD -6.25%
Weighted Average Number of Shares Outstanding, Basic 17.2M shares +6.99%
Weighted Average Number of Shares Outstanding, Diluted 17.2M shares +6.99%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 12.7M USD -18.2%
General and Administrative Expense 7.58M USD +3.84%
Operating Income (Loss) -20.3M USD +11.2%
Net Income (Loss) Attributable to Parent -19.4M USD +13.3%
Earnings Per Share, Basic -1.16 USD/shares +23.2%
Earnings Per Share, Diluted -1.16 USD/shares +23.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.2M USD -22.2%
Other Assets, Current 138K USD -32%
Assets, Current 17.3M USD -22.3%
Assets 17.3M USD -22.3%
Accounts Payable, Current 2.26M USD -35.3%
Employee-related Liabilities, Current 3.77M USD +95.9%
Accrued Liabilities, Current 282K USD +78.5%
Liabilities, Current 6.32M USD +13.3%
Liabilities 6.32M USD +13.3%
Retained Earnings (Accumulated Deficit) -67M USD -40.7%
Stockholders' Equity Attributable to Parent 11M USD -34.1%
Liabilities and Equity 17.3M USD -22.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.36M USD +8.77%
Net Cash Provided by (Used in) Financing Activities 4.7M USD +1763%
Common Stock, Shares Authorized 60M shares 0%
Common Stock, Shares, Issued 19M shares +9.68%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 17.2M USD -22.2%
Deferred Tax Assets, Valuation Allowance 14.5M USD +69%
Deferred Tax Assets, Gross 14.5M USD +69%
Deferred Tax Assets, Operating Loss Carryforwards 9.63M USD +57.3%
Additional Paid in Capital 78M USD +21.3%
Deferred Tax Assets, Net of Valuation Allowance 0 USD